Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) on March 11 announced that it has appointed José Baselga M.D., Ph.D. and Jeff Berkowitz as independent members of its board of directors. Infinity Pharmaceuticals Inc. (NASDAQ:INFI) shares after opening at $11.34 moved to $11.38 on last trade day and at the end of the day closed at $10.95. Company price to cash ratio as 2.47. Infinity Pharmaceuticals Inc. (NASDAQ:INFI) showed a negative weekly performance of -14.79%.
Onconova Therapeutics Inc. (NASDAQ:ONTX) recognized revenues of $4.8 million, $46.2 million and $1.5 million for the years ended December 31, 2013, 2012 and 2011, respectively. As of December 31, 2013, and had an accumulated deficit of $230.9 million. Onconova Therapeutics Inc. (NASDAQ:ONTX) shares fell -2.10% in last trading session and ended the day on $6.06. ONTX return on equity ratio is recorded as 113.70% and its return on assets is -114.60%.
Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) is another company with an outstanding RNAi platform, and based on price targets, it could be a huge winner if successful. Dicerna has selected its first liver-targeted clinical candidate, primary hyperoxaluria, and expects to enter the clinic by early 2015, with data in its first indication by mid-2015. Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) shares moved down -6.78% in last trading session and was closed at $23.50, while trading in range of $23.36 – $25.72. Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) year to date (YTD) performance is -45.85%.
Akebia Therapeutics, Inc. (NASDAQ:AKBA) a biopharmaceutical company focused on the development of novel, proprietary therapeutics based on hypoxia-inducible factor biology and the commercialization of these products for patients with kidney disease, on 26 march announced the closing of its initial public offering of 6,762,000 shares of common stock at an initial public offering price of $17.00 per share. Akebia Therapeutics Inc. (NASDAQ:AKBA) weekly performance is -1.14%. On last trading day company shares ended up $19.15. Akebia Therapeutics Inc. (NASDAQ:AKBA) distance from 50-day simple moving average (SMA50) is -9.21%.